Advertisement


Andrew J. Armstrong, MD, ScM, on New Treatment Options in Castration-Resistant Prostate Cancer

2015 NCCN Annual Conference

Advertisement

Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.



Related Videos

Gynecologic Cancers

Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe

Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with dif...

Gastroesophageal Cancer

Hans Gerdes, MD, on Endoscopic Therapies for Early-Stage Esophageal Cancers

Hans Gerdes, MD, of Memorial Sloan Kettering Cancer Center, discusses a new approach to the management of early-stage esophageal cancers with endoscopic resections.

Lymphoma

Andrew D. Zelenetz, MD, PhD, on Emerging Treatment Options for Lymphomas

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzum...

Breast Cancer

Amy Cyr, MD on Advances in Management of Early-Stage Breast Cancer

Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast can...

Skin Cancer
Symptom Management

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocia...

Advertisement

Advertisement



Advertisement